Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy?
· fool.com · popularity 17/100 · 0 similar stories today · Entrepreneurship & Startups (Business & Finance)
Read the original at fool.com →
Summary
The stock is expensive, but the potential market for GLP-1 drugs is likely much larger than forecast. After a 57% run-up over the past 52 weeks, Eli …
Found in: The Motley Fool. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 15.